Nuvectis Pharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $-10.0K | — |
| FY2021 | — | $-11.0M | $5.7M |
| FY2022 | — | $14.2M | $20.0M |
| FY2023 | — | $12.2M | $19.1M |
| FY2024 | — | $9.7M | $18.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $-10.0K | — |
| FY2021 | — | $-11.0M | $5.7M |
| FY2022 | — | $14.2M | $20.0M |
| FY2023 | — | $12.2M | $19.1M |
| FY2024 | — | $9.7M | $18.5M |